ConductScience.org, home

Comparison · NCT03472495-2dc83025

Oral Immediate Release Diltiazem vs Continuous Infusion IV Diltiazem: Adverse Event Rate

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Oral Immediate Release Diltiazem vs Continuous Infusion IV Diltiazem: Adverse Event Rate. Trial comparisons, record NCT03472495-2dc83025. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03472495-2dc83025

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1250.02240.471wilson
Risk in group 200.00000000000000002780.39wilson
Risk difference, group 1 minus group 20.125-0.2790.471newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one more participant with the outcome on Oral Immediate Release Diltiazem than on Continuous Infusion IV Diltiazem8from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Oral Immediate Release DiltiazemDiltiazem immediate release 60mg orally once (Diltiazem oral product)~Diltiazem Oral Product: Diltiazem Immediate Release 60 MG PO Q6H (30 MG PO Q6H if patient is \<60 kg)18OG000
Group 2Continuous Infusion IV Diltiazem
Diltiazem 2.5-5 mg/hour intravenous Titrate by 1.25 mg every 15-60 minutes. Maximum titration dose 15 mg/hour. Titration Goal of HR \<110 (Diltiazem Injectable Product)~Diltiazem Injectable Product: Diltiazem Continuous Infusion Titrated
06OG001

Outcome

Type
SECONDARY
Title
Adverse Event Rate
Description
Number of participants with heart rate or blood pressure adverse events: Heart rate \< 60 beats/min, or systolic blood pressure \<90 mmHg requiring intervention (intravenous fluid bolus, vasopressors, medication discontinuation)
Time frame
4 hrs
Population

Source ClinicalTrials.gov

Trial

Title
Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial
NCT number
NCT03472495
Phases
PHASE4
Conditions
Atrial Fibrillation and Flutter
Interventions
Diltiazem Oral Product, Diltiazem Injectable Product
Lead sponsor
Virginia Commonwealth University
Results first posted
2023-03-01

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03472495-2dc83025